ProfileGDS5678 / 1451448_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 82% 82% 84% 81% 82% 79% 83% 82% 80% 81% 81% 79% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7059481
GSM967853U87-EV human glioblastoma xenograft - Control 25.91282
GSM967854U87-EV human glioblastoma xenograft - Control 35.8808682
GSM967855U87-EV human glioblastoma xenograft - Control 46.4443884
GSM967856U87-EV human glioblastoma xenograft - Control 55.9027981
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.74782
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.378679
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.984283
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9272182
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7670280
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7654981
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8240681
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.5721479
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7432781